ClinicalTrials.gg
CompletedNCT00686725Updated Jun 14, 2017Results posted

Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)

A Phase 4 interventional study of Temozolomide and Radiotherapy in Glioblastoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-06-14.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.

Enrollment
41st of 221
99 · median 41
Started
2008
with 10 others
Phase 4
2 of 232
none open now
Registered
80th of 232
by date
Lead sponsor
4 of 232
Merck Sharp & Dohme LLC

Among the 232 studies testing temozolomide in Glioblastoma, this one is the 41st largest by enrollment of the 221 interventional ones that give a count, is one of 11 that started in 2008, is one of 2 in phase 4, and was the 80th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies testing temozolomide in Glioblastoma, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the efficacy and safety of early postsurgery temozolomide chemotherapy followed by the standard temozolomide regimen, compared to the standard regimen alone, for the treatment of patients with newly diagnosed glioblastoma multiforme.

03

Conditions studied

  • Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Only the patients who meet all these criteria can be enrolled in the study:

  • Patients with prior histological confirmation of newly diagnosed primary glioblastoma multiforme in supratentorial cerebral hemisphere.
  • Gross total resection or partial resection (imaging) >70%.
  • At least be capable to obtain a tissue sample for MGMT analysis during surgery.
  • Chemo-radiotherapy to be expected from Week 5 (Day 29) after surgery.
  • Age >=18 and \<=70 years.
  • (ECOG) performance status of 0, 1, or 2.
  • >=9 months.
  • Laboratory test values must satisfy the following criteria:

    • >=1.5 x 10\^9/L;
    • count >=100 x 10\^9/L;
    • >=80 g/L;
    • blood urea nitrogen and creatinine \< 1.5 x value (ULN);
    • total and direct bilirubin \< 1.5 x ULN;
    • and aspartate aminotransferase \< 3 x ULN;
    • alkaline phosphatase \< 2 x ULN.
  • Patients must be willing to provide written .
  • Patients of (including female subjects and the female partners of male subjects) must use an effective method of .

Exclusion criteria

Exclusion Criteria:

Patients will not be enrolled if any of the following criteria apply:

  • Patient with previous or current (except melanoma) at other sites, unless disease free for at least 3 years.
  • Patient who received chemotherapy, radiotherapy for study indication, or other medications for antitumor indication prior to surgery.
  • Patient with recurrent or multiple malignant glioma (including gliomatosis cerebri).
  • Patient with lesions at the subtentorial or outside of calvaria.
  • Patient who received chemotherapy or radiotherapy sensitizers for head or neck tumor.
  • Patient who received radiotherapy at head or neck which leads to radiotherapy domain overlapping.
  • Patient with acute infections requiring intravenous antibiotics.
  • Frequent vomiting or medical condition that could interfere with oral medication intake (eg, partial bowel obstruction).
  • Known (HIV)-positive or acquired immune deficiency syndrome (AIDS)-related illness.
  • Woman who is pregnant or breastfeeding.
  • Patient with a history of to temozolomide or other analogic alkylating agents.
  • Patient with any other conditions under which investigators think the subject is not suitable for enrolment, such like having known that the subject may not have good compliance.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Active comparator
    Temozolomide + Radiation

    Standard therapy regimen: Treatment will start 4 weeks after surgery. Temozolomide will be administered concomitantly with radiotherapy, at 75 mg/m\^2/day orally for 42 days. Four weeks after completing concomitant radiotherapy, temozolomide will be administered for an additional six cycles. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m\^2/day, and may be increased to 200 mg/m\^2/day for Cycle 2 and subsequent cycles depending on nonhematological toxicity observed and neutrophil and platelet count values. Capsules containing 20 mg or 100 mg of temozolomide will be used. Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks.

    Drug: Temozolomide · Radiation: Radiotherapy

  • Experimental
    Temozolomide alone, then Temozolomide + Radiation

    Early postsurgery temozolomide chemotherapy plus standard regimen: Treatment with temozolomide alone will start 2 weeks after surgery at 75 mg/m\^2/day orally for 14 days. Then, starting on Day 29 after surgery, temozolomide will be administered according to standard treatment as described for the temozolomide + radiation arm (standard therapy regimen). Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks.

    Drug: Temozolomide · Radiation: Radiotherapy

Interventions

  • Also known as: Temodal, Temodar, SCH 052365

  • RadiationRadiotherapy

    Also known as: Irradiation, radiation therapy

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death. OS was calculated by the Kaplan-Meier method.

    Time frame: Up to 2 years

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the length of time from randomization to disease progression (the length of time during which the cancer did not get worse) or death. PFS was calculated by the Kaplan-Meier method.

    Time frame: Up to 2 years

  2. Objective Tumor Assessment After Surgery: Overall Response

    Overall response was based on neuroimaging (magnetic resonance imaging \[MRI\]), clinical neurological examination, and steroid administration. It was assessed as follows: Complete Response (CR): Disappearance of all enhancing tumor (measurable or non-measurable), no corticosteroid use, and neurologically stable or improved. Partial Response (PR): ≥50% reduction in size of enhancing tumor (measurable or non-measurable) for any measurable lesions or definite improvement for any non-measurable lesions, corticosteroid dosage stable or reduced, and neurologically stable or improved. Progressive Disease (PD): ≥25% increase in contrast enhancement for any measurable lesions or definite worsening for any non-measurable lesions, or any new tumor on MRI scans, at an increased dose of corticosteroid, with or without neurologic progression. Clinical or radiological worsening resulting from other than tumor factors were excluded. Stable Disease (SD): All other situations.

    Time frame: Up to 2 years

  3. Relationship Between O6-methylguanine-DNA Methyltransferase (MGMT) Status and Therapy Response: Overall Survival for the MGMT Positive Group

    MGMT was measured by immunohistochemistry (IHC). OS was defined as the length of time from the start of treatment that 1/2 of the participants were still alive. OS was calculated by the Kaplan-Meier method.

    Time frame: Up to 2 years

  4. Relationship Between MGMT Status and Therapy Response: Overall Survival for the MGMT Negative Group

    MGMT was measured by IHC. OS was defined as the length of time from the start of treatment that 1/2 of the participants were still alive. OS was calculated by the Kaplan-Meier method.

    Time frame: Up to 2 years

  5. Relationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Positive Group

    MGMT was measured by IHC. OS rate was defined as the percentage of participants who were still alive 6, 12, \& 18 months after starting study treatment. OS was calculated by the Kaplan-Meier method.

    Time frame: 6, 12, & 18 months

  6. Relationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Negative Group

    MGMT was measured by IHC. OS rate was defined as the percentage of participants who were still alive 6, 12, \& 18 months after starting study treatment. OS was calculated by the Kaplan-Meier method.

    Time frame: 6, 12, & 18 months

  7. Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Positive Group

    MGMT was measured by IHC. PFS: The length of time during and after treatment that a participant lived with the cancer but it does not get worse. PFS was calculated by the Kaplan-Meier method.

    Time frame: Up to 2 years

  8. Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Negative Group

    MGMT was measured by IHC. PFS: The length of time during and after treatment that a participant lived with the cancer but it does not get worse. PFS was calculated by the Kaplan-Meier method.

    Time frame: Up to 2 years

07

Results

Posted Apr 4, 2013

Participant flow

Participant flow — Overall Study
MilestoneTemozolomide + RadiationTemozolomide Alone, Then Temozolomide + Radiation
Started4752
Completed110
Not completed4642
Withdrew: Adverse event11
Withdrew: Progressive disease1723
Withdrew: Lost to follow-up75
Withdrew: Death63
Withdrew: Withdrawal by subject134
Withdrew: Protocol violation13
Withdrew: Other13

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death. OS was calculated by the Kaplan-Meier method.

Time frame:
Up to 2 years
Reported as:
Median · months
Overall Survival (OS)
monthsTemozolomide + RadiationTemozolomide Alone, Then Temozolomide + Radiation
Overall Survival (OS)13.17 (11.14 to 18.76)17.58 (15.18 to 23.03)
SecondaryProgression-Free Survival (PFS)

PFS was defined as the length of time from randomization to disease progression (the length of time during which the cancer did not get worse) or death. PFS was calculated by the Kaplan-Meier method.

Time frame:
Up to 2 years
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsTemozolomide + RadiationTemozolomide Alone, Then Temozolomide + Radiation
Progression-Free Survival (PFS)10.38 (8.18 to 15.44)8.74 (6.41 to 14.85)
SecondaryObjective Tumor Assessment After Surgery: Overall Response

Overall response was based on neuroimaging (magnetic resonance imaging \[MRI\]), clinical neurological examination, and steroid administration. It was assessed as follows: Complete Response (CR): Disappearance of all enhancing tumor (measurable or non-measurable), no corticosteroid use, and neurologically stable or improved. Partial Response (PR): ≥50% reduction in size of enhancing tumor (measurable or non-measurable) for any measurable lesions or definite improvement for any non-measurable lesions, corticosteroid dosage stable or reduced, and neurologically stable or improved. Progressive Disease (PD): ≥25% increase in contrast enhancement for any measurable lesions or definite worsening for any non-measurable lesions, or any new tumor on MRI scans, at an increased dose of corticosteroid, with or without neurologic progression. Clinical or radiological worsening resulting from other than tumor factors were excluded. Stable Disease (SD): All other situations.

Time frame:
Up to 2 years
Reported as:
Number · participants
Objective Tumor Assessment After Surgery: Overall Response
participantsTemozolomide + RadiationTemozolomide Alone, Then Temozolomide + Radiation
CR10
PR00
SD3847
PD34
No overall response data available51
SecondaryRelationship Between O6-methylguanine-DNA Methyltransferase (MGMT) Status and Therapy Response: Overall Survival for the MGMT Positive Group

MGMT was measured by immunohistochemistry (IHC). OS was defined as the length of time from the start of treatment that 1/2 of the participants were still alive. OS was calculated by the Kaplan-Meier method.

Time frame:
Up to 2 years
Reported as:
Median · months
Relationship Between O6-methylguanine-DNA Methyltransferase (MGMT) Status and Therapy Response: Overall Survival for the MGMT Positive Group
monthsTemozolomide + RadiationTemozolomide Alone, Then Temozolomide + Radiation
Relationship Between O6-methylguanine-DNA Methyltransferase (MGMT) Status and Therapy Response: Overall Survival for the MGMT Positive Group14.4 ± 2.38517.49 ± 1.491
Statistical analysis
  • Temozolomide + Radiation vs Temozolomide Alone, Then Temozolomide + Radiation · Log Rank · p = 0.183
SecondaryRelationship Between MGMT Status and Therapy Response: Overall Survival for the MGMT Negative Group

MGMT was measured by IHC. OS was defined as the length of time from the start of treatment that 1/2 of the participants were still alive. OS was calculated by the Kaplan-Meier method.

Time frame:
Up to 2 years
Reported as:
Median · months
Relationship Between MGMT Status and Therapy Response: Overall Survival for the MGMT Negative Group
monthsTemozolomide + RadiationTemozolomide Alone, Then Temozolomide + Radiation
Relationship Between MGMT Status and Therapy Response: Overall Survival for the MGMT Negative Group13.81 ± 1.41715.12 ± 1.171
Statistical analysis
  • Temozolomide + Radiation vs Temozolomide Alone, Then Temozolomide + Radiation · Log Rank · p = 0.35
SecondaryRelationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Positive Group

MGMT was measured by IHC. OS rate was defined as the percentage of participants who were still alive 6, 12, \& 18 months after starting study treatment. OS was calculated by the Kaplan-Meier method.

Time frame:
6, 12, & 18 months
Reported as:
Number · percentage of participants
Relationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Positive Group
percentage of participantsTemozolomide + RadiationTemozolomide Alone, Then Temozolomide + Radiation
6 months80.8 (42.3 to 94.9)89.2 (63.1 to 97.2)
12 months69.3 (31.2 to 89.1)82.8 (55.4 to 94.2)
18 months36.9 (6.5 to 69.6)66.2 (35.7 to 84.8)
SecondaryRelationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Negative Group

MGMT was measured by IHC. OS rate was defined as the percentage of participants who were still alive 6, 12, \& 18 months after starting study treatment. OS was calculated by the Kaplan-Meier method.

Time frame:
6, 12, & 18 months
Reported as:
Number · percentage of participants
Relationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Negative Group
percentage of participantsTemozolomide + RadiationTemozolomide Alone, Then Temozolomide + Radiation
6 months87.5 (66.1 to 95.8)95.8 (73.9 to 99.4)
12 months57.7 (31.9 to 76.8)81.4 (57.5 to 92.6)
18 months44.9 (21.1 to 66.3)26.7 (9.1 to 48.3)
SecondaryRelationship Between MGMT Status and Therapy Response: PFS for the MGMT Positive Group

MGMT was measured by IHC. PFS: The length of time during and after treatment that a participant lived with the cancer but it does not get worse. PFS was calculated by the Kaplan-Meier method.

Time frame:
Up to 2 years
Reported as:
Median · months
Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Positive Group
monthsTemozolomide + RadiationTemozolomide Alone, Then Temozolomide + Radiation
Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Positive Group10.04 ± 2.09411.19 ± 1.882
Statistical analysis
  • Temozolomide + Radiation vs Temozolomide Alone, Then Temozolomide + Radiation · Log Rank · p = 0.648
SecondaryRelationship Between MGMT Status and Therapy Response: PFS for the MGMT Negative Group

MGMT was measured by IHC. PFS: The length of time during and after treatment that a participant lived with the cancer but it does not get worse. PFS was calculated by the Kaplan-Meier method.

Time frame:
Up to 2 years
Reported as:
Median · months
Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Negative Group
monthsTemozolomide + RadiationTemozolomide Alone, Then Temozolomide + Radiation
Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Negative Group11.11 ± 1.44110.46 ± 1.475
Statistical analysis
  • Temozolomide + Radiation vs Temozolomide Alone, Then Temozolomide + Radiation · Log Rank · p = 0.915

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Temozolomide Radiation—11/42 (26.2%)24/42 (57.1%)
Temozolomide Alone, Then Temozolomide Radiation—11/52 (21.2%)22/52 (42.3%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventTemozolomide RadiationTemozolomide Alone, Then Temozolomide Radiation
NEOPLASM RECURRENCENeoplasms benign, malignant and unspecified (incl cysts and polyps)4/425/52
DISEASE PROGRESSIONGeneral disorders3/422/52
NAUSEAGastrointestinal disorders1/420/52
VOMITINGGastrointestinal disorders1/420/52
DISEASE RECURRENCEGeneral disorders1/420/52
HEPATIC FAILUREHepatobiliary disorders1/420/52
EPILEPSYNervous system disorders1/420/52
HEADACHENervous system disorders1/420/52
RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders1/421/52
CENTRAL NERVOUS SYSTEM INFECTIONInfections and infestations0/421/52
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTemozolomide RadiationTemozolomide Alone, Then Temozolomide Radiation
NAUSEAGastrointestinal disorders13/427/52
VOMITINGGastrointestinal disorders12/424/52
HEADACHENervous system disorders10/422/52
PYREXIAGeneral disorders5/423/52
DECREASED APPETITEMetabolism and nutrition disorders4/422/52
DIZZINESSNervous system disorders0/424/52
EPILEPSYNervous system disorders1/424/52
GAIT DISTURBANCEGeneral disorders3/420/52
CONSTIPATIONGastrointestinal disorders0/423/52
INTRACRANIAL PRESSURE INCREASEDNervous system disorders0/423/52

Baseline characteristics

Age, Continuous
Age, Continuous(years)Temozolomide + RadiationTemozolomide Alone, Then Temozolomide + RadiationTotal
Mean52.1 ± 10.1248.5 ± 13.0450.2 ± 11.82
Sex: Female, Male
Sex: Female, Male(Participants)Temozolomide + RadiationTemozolomide Alone, Then Temozolomide + RadiationTotal
Female132033
Male343266
Region of Enrollment
Region of Enrollment(participants)Temozolomide + RadiationTemozolomide Alone, Then Temozolomide + RadiationTotal
China475299
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Mao Y, Yao Y, Zhang LW, Lu YC, Chen ZP, Zhang JM, Qi ST, You C, Wang RZ, Yang SY, Zhang X, Wang JS, Chen JX, Yang QY, Shen H, Li ZY, Wang X, Ma WB, Yang XJ, Zhen HN, Zhou LF. Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial. Chin Med J (Engl). 2015 Oct 20;128(20):2751-8. doi: 10.4103/0366-6999.167313. PubMed 26481741 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2008 to primary completion in Sep 2011, 39 months.

Results were first posted in Apr 2013, 1 year 6 months after primary completion. A results delay was requested in Sep 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 30, 2008
StartActual
Jun 24, 2008
Primary completionActual
Sep 28, 2011
CompletionActual
Sep 28, 2011
Results delay requested
Sep 28, 2012
Results first posted
Apr 4, 2013
Last update
Jun 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00686725
Responsible party
Sponsor
First posted
May 30, 2008
Start date
Jun 24, 2008
Primary completion
Sep 28, 2011
Completion
Sep 28, 2011
Results posted
Apr 4, 2013
Last update
Jun 14, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion